| Bioactivity | Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca2+ release[1][2][3]. |
| Invitro | Biacetyl monoxime (Diacetyl monoxime) (50 mM, 6 and 48 h) decreases cellulase secretion in C. cinerea[1].Biacetyl monoxime (50 mM, 2 and 4 h) disrupts the localization of the Golgi apparatus, but not that of the endoplasmic reticulum[1].Biacetyl monoxime (0-30 mM) induces SR Ca2+ release (no efflux inhibitors) in a concentration-dependent manner, with a maximal reduction of 72% of SR Ca2+ at pCa 6.0[2].Biacetyl monoxime acts as a chemical phosphatase, which has led to speculation that dephosphorylation of key Ca2+ channel proteins may be involved in its inhibition of contraction[2].Biacetyl monoxime does not inhibit the ATPase activity of two different myosin-I isoforms, myosin-V, or myosin-VI[3].Biacetyl monoxime (0-50 mM) suppresses L-type Ca2+ current of single cardiac myocytes isolated from SHR and WKY rats[4].Biacetyl monoxime significantly reduces the duration of both spontaneous and electrically stimulated action potentials of cultured neonatal rat cardiomyocytes[4]. |
| In Vivo | Biacetyl monoxime (0-200 mg/kg; i.v.; once) shows hypotensive effect[4].Biacetyl monoxime (0-205 mg/kg; i.p.; once) shows anticonvulsant effect against Picrotoxin (HY-101391)-induced convulsions[5]. Animal Model: |
| Name | Biacetyl monoxime |
| CAS | 57-71-6 |
| Formula | C4H7NO2 |
| Molar Mass | 101.10 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Kohsuke Hashimoto, et al. The myosin ATPase inhibitor, 2,3-butanedione 2-monoxime, prevents protein secretion by the basidiomycete Coprinopsis cinerea. Biotechnol Lett. 2011 Apr;33(4):769-75. [2]. R M Phillips, et al. 2,3-Butanedione 2-monoxime (BDM) induces calcium release from canine cardiac sarcoplasmic reticulum. Biochem Biophys Res Commun. 1996 Dec 4;229(1):154-7. [3]. Ostap EM. 2,3-Butanedione monoxime (BDM) as a myosin inhibitor. J Muscle Res Cell Motil. 2002;23(4):305-8. [4]. Xiao YF, et al. Effects of 2,3-butanedione monoxime on blood pressure, myocardial Ca2+ currents, and action potentials of rats. Am J Hypertens. 1995 Dec;8(12 Pt 1):1232-40. [5]. Brightman T, et al. 2,3-Butanedione monoxime protects mice against the convulsant effect of picrotoxin by facilitating GABA-activated currents. Brain Res. 1995 Apr 24;678(1-2):110-6. |
Biacetyl monoxime
CAS: 57-71-6 F: C4H7NO2 W: 101.10
Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.